Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 known ✓ | P03952 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.95 |
| ▸ | F10 | P00742 | 1/20 | 0.95 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.64 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.64 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.64 |
| ▸ | F2 | P00734 | 6/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PLAU | P00749 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | MASP2 | O00187 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | PLG | P00747 | 2/20 | 0.52 |
| ▸ | C1S | P09871 | 1/20 | 0.52 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1981173 | 1.00 | LOXL2 (0.95) | LOXL2F10ST14PRSS1PRSS3 | |
| SCHEMBL49594 | 0.98 | LOXL2 (1.00) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL10925118 | 0.94 | LOXL2 (0.83) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL10919747 | 0.88 | LOXL2 (0.74) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL10919741 | 0.88 | LOXL2 (0.74) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL27771922 | 0.87 | LOXL2 (0.71) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL8173513 | 0.82 | F10 (0.65) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL392375 | 0.82 | PRSS1 (0.78) | LOXL2F10ST14PRSS1PRSS3 | |
| Hydrochloric Acid SCHEMBL30999366 | 0.82 | PRSS1 (0.78) | LOXL2F10ST14PRSS1PRSS3 | |
| SCHEMBL10922350 | 0.81 | F2 (0.86) | LOXL2F10ST14PRSS1PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4561993-A1 | INHIBITORS OF PLASMA KALLIKREIN | Rezolute, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120051460-A | Plasma kallikrein inhibitors | 瑞泽路特有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-119836420-A | 2-Indolone compounds as VEGFR and PKa dual-target inhibitors, preparation method and application thereof | 远森制药（杭州）有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-113795249-B | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4494698-A2 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2025-01-22 | — | — | EP | disclosed |
| EP-3661922-B1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-23 | — | — | EP | disclosed |
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-20 | — | — | US | disclosed |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-20 | — | — | US | disclosed |
| WO-2024025907-A1 | INHIBITORS OF PLASMA KALLIKREIN | REZOLUTE, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-2131861-A2 | INTEGRATED PHOTOACTIVE SMALL MOLECULES AND USES THEREOF | Mallinckrodt Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| CN-101500594-A | Methods and compositions for treating ophthalmic conditions via modulation of megalin activity | SIRION THERAPEUTICS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008108944-A2 | INTEGRATED PHOTOACTIVE SMALL MOLECULES AND USES THEREOF | MALLINCKRODT INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20050245511-A1 | Novel compounds that inhibit tryptase activity | MORPHOCHEM AG | 2005-11-03 | — | — | US | disclosed |
| EP-1206444-B1 | COMPOUNDS THAT INHIBIT TRYPTASE ACTIVITY | MORPHOCHEM AG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-20020137687-A1 | Novel compounds that inhibit tryptase activity | MORPHOCHEM AG (DE) | 2002-09-26 | — | — | US | disclosed |
| US-6384222-B1 | BRADYKININ HORMONE ANTAGONIST; ANALGESIC, ANTIINFLAMMATORY; ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS; ETHERIFICATION, AMIDATION | FOURNIER INDUSTRIE ET SANTE (FR) | 2002-05-07 | — | — | US | disclosed |
| US-6063791-A | N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use | FOURNIER INDUSTRIE ET SANTE (FR) | 2000-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199602-A1 | INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF | KLKB1, KLK1, KLK5 | KLKB1 1/4885LOXL2 452/4885F10 442/4885 |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | KLKB1 62/4885LOXL2 726/4885F10 125/4885 |
| US-20020137687-A1 | Novel compounds that inhibit tryptase activity | TPSAB1, TPSB2, CMA1 | KLKB1 357/4885LOXL2 1348/4885F10 460/4885 |
| US-20050245511-A1 | Novel compounds that inhibit tryptase activity | TPSB2, TPSAB1, CMA1 | KLKB1 356/4885LOXL2 1131/4885F10 564/4885 |
| US-20090098145-A1 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | ALDH1A2, PDE6C, EYA2 | KLKB1 2808/4885LOXL2 741/4885F10 4758/4885 |
| US-11905285-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | KLKB1 1/4885LOXL2 452/4885F10 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.